Sutro Biopharma Inc

NASDAQ:STRO   4:00:00 PM EDT
7.41
+0.02 (+0.27%)
5:13:44 PM EDT: $7.78 +0.37 (+4.99%)
Earnings Announcements

Sutro Biopharma Reports Third Quarter 2022 Financial Results

Published: 11/08/2022 21:52 GMT
Sutro Biopharma Inc (STRO) - Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones.
Cash, Cash Equivalents and Marketable Securities As of June 30, 2022 Provides a Projected Cash Runway Into First Half of 2024.
Q3 Revenue $25.1 Million Versus $8.5 Million.
Q3 Earnings per Share View $-0.74, Revenue View $12.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $13.16 Million
Adjusted EPS is expected to be -$0.65

Next Quarter Revenue Guidance is expected to be $14.71 Million
Next Quarter EPS Guidance is expected to be -$0.62

More details on our Analysts Page.